Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Multicenter, Open-label Study of IBI3003 in Participants With Relapsed or Refractory Multiple Myeloma

NCT07336472 is registered in ClinicalTrials.gov with Fortvita Biologics (USA)Inc. as lead sponsor.

NCT NCT07336472
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07336472 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Multicenter, Open-label Study of IBI3003 in Participants With Relapsed or Refractory Multiple Myeloma
Lead sponsor
Fortvita Biologics (USA)Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 30, 2026
Completion date
September 30, 2028
Enrollment
360 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma